Yissum's technologies presented at Biomed 2008: An Assay and Kit and Device for Removing Amylase from Body Fluids and A Novel Anti-Inflammatory Agent
Economist: HUJI researcher Boris Rubinsky and his colleagues at Berkeley think they could help make medical imagining simpler, cheaper and more widely available. His team report in a recent issue of Public Library of Science (PloS) ONE on a design to use mobile phones to send raw imaging data to a base where it could be processed with the sophisticated software needed to create a medical image. The image could then be returned to the mobile phone and viewed on it. The mobile phone may join the stethoscope and the thermometer as an indispensable piece of medical kit.
Israeli Technology Transfer companies have become a role model for foreign academic institutes.
In 2006 researchers from the Hebrew University in Israel isolated a variant of the virus that causes Newcastle disease, a highly contagious disease in birds that can kill. This variant was able to target selectively cancer cells in humans. Trials on a form of aggressive primary brain tumour have shown one complete regression out of 14 treated patients.
Sophisticated medical images such as MRI and ultrasound scans and x-rays can be sent via cellular phones using a process developed at the Hebrew University of Jerusalem. The new technology, jointly owned by Yissum and the University of California is expected to be a boon not only for patients in developed counties, including rural areas with reduced access to medical services, but especially for those in the Third World.
Hybridization of biological and electric systems can serve as the basis for diverse applications ranging from biosensors and drug screening systems to neuro-electronic computers. Our technology enables the hybridization by creating an innovative physical linkage between cells and surface substrates, and using ion-sensitive field- effect transistors (ISFET) to transform the biological activity into readable electronic signals
Hebrew University researchers have recently developed a bio-electronic sensor for the detection of chemicals such as nerve gases and insecticides by irreversible inhibition of the enzyme acetylcholine esterase.
The Israeli start-up company, Nanolymf Ltd, believes its technology has the potential to allow the oral administration of some of the biggest intravenous and injectable drugs on today’s market.
Instead of asking friends "How do you feel?" or doctors examining patients, one day such queries and examinations may be replaced by tiny radio antennas implanted under the skin to act as remote sensors of humans' emotional, physiological state. Scientists at the Hebrew University's applied physics department have discovered a method for remote sensing of people's physiological and emotional state.
Recent research conducted by Dr. Hermona Soreq and co-workers at the
Alexander Silberman Life Sciences Institute at The Hebrew University of
Jerusalem, in collaboration with PharmAthene, examined the role of rBChE in
the prevention of amyloid plaques, which are believed to play a role in the
development of Alzheimer's disease.
The innovative cationic emulsion for the treatment of dry eye symptoms is the first product developed from its pipeline to be marketed
The company raised the finance from Docor International, Moshe (Mori) Arkin and a number of undisclosed institutional investors.
Yissum Technology Transfer Company of the Hebrew University of Jerusalem ended 2007 with $51 million revenue, 27% more than in 2006.
Nava Swersky Sofer congratulating Israel on it's 60th anniversary on a special Forbes edition.
The unique case-controlled DNA database for genetic association studies will allow the scientific community to access DNA samples directly via the Internet (www.hugr.org) and test genes of interest.
The Hebrew University Genetic Resource (HUGR) platform includes 15,000 DNA samples of Ashkenazi Jews
Scientists from the School of Pharmacy at the Hebrew University of Jerusalem discovered a novel orally available drug that prevents metastasis formation in various types of cancers.
Yissum spin-off Morria Biopharmaceuticals, a biopharmaceutical company focused on the development of novel anti- inflammatory drugs, announced the preliminary safety results from its Phase I safety and tolerability study of MRX-4 in 16 patients suffering from allergic rhinitis (AR).
Globes article portraying Israeli Technology Transfer (Hebrew)